İsteğe bağlı ürün analizi
İzninizle, hangi araştırma yolculuklarının işe yaradığını anlamak için gizliliği gözeten sınırlı analizler kullanırız. Reklam izleyicileri veya oturum kaydı kullanmayız. Bu seçimi Tercihler bölümünden değiştirebilirsiniz. Okuyun Gizlilik Politikası.
The biggest growth opportunity is the accelerated replacement of the 12,000-unit installed instrument base (including 4,500 units in the U.S.
Biopharmaceutical customer capital expenditure retrenchment and spending freezes causing consolidated operating margin to decline below 22.5%.
At a share price of $425.21 (as of 2026-10-02), the stock trades at a 23.13% premium to fair value, implying an expected return of -18.78%. Although Waters commands a wide economic moat rooted in high regulatory switching costs across an installed base of 12,000 instruments and recurring consumables and service revenues representing 57.5% of net sales, valuation multiples of 24.75x forward earnings fully price in multi-year recovery and leave no margin of safety against biopharmaceutical capital expenditure deferrals, Chinese healthcare procurement headwinds, and foreign exchange translation pressure.
Waters Corporation possesses exceptional business quality, supported by a wide economic moat that derives from deep workflow integration, proprietary Empower chromatography data software, and an active installed base of 12,000 instruments ripe for replacement. In FY2025, the business generated $3,165.29 million in consolidated revenue and $802.59 million in operating income, backed by strong recurring revenue from chemistry consumables ($631.46 million) and service agreements ($1,188.19 million). Analytical testing workflows in pharmaceutical development and commercial lot release face stringent FDA and EMA regulatory validation hurdles, creating formidable customer switching barriers. This installed base moat drives consistent cash conversion, yielding $652.56 million in operating cash flow and $539.81 million in free cash flow in FY2025.5678
Despite these franchise strengths, current valuation leaves the stock vulnerable. Waters trades at $425.21 (as of 2026-10-02), corresponding to 24.75x forward earnings and a 23.13% premium to our fair value midpoint of $345.34. Our fair value sits 15.7% below the present-value equivalent ($409.43) of the analyst consensus 12-month price target of $448.91 discounted at the cost of equity of 9.64%. Comprehensive valuation modeling under a 9.10% WACC and an exit multiple of 22.0x indicates that the market has fully capitalized expected medium-term operating margin expansion from 25.50% to 27.20% without providing adequate protection against operational setbacks.24
Near-term macro and cyclical friction underscores the necessity of a cautious stance. Pharmaceutical customers generate 59.0% of total revenue, exposing the company to biopharma capital expenditure deferrals and extended sales cycles for new instruments ($1,977.10 million product revenue base). In China, which accounted for $437.47 million or 13.8% of FY2025 revenue, hospital procurement anti-corruption campaigns and DRG reform continue to delay tender releases until Q4 2026. Furthermore, foreign exchange translation has created a $0.25 drag on diluted EPS while distributor inventory timing swings add quarterly revenue distortion. With an implied return of -18.78%, we recommend reducing exposure.58
Waters analytical instruments, including liquid chromatography and mass spectrometry systems, are integrated directly into validated pharmaceutical drug batch release and QA/QC workflows governed by FDA and EMA compliance. Once a method is validated on Waters Empower software and proprietary column chemistries, switching to competing platforms requires costly and time-consuming method re-validation, protecting the company's installed base of 12,000 instruments.5
Over half of consolidated revenue is recurring, with chemistry consumables ($631.46M in FY2025) and service agreements ($1,188.19M in FY2025) comprising 57.5% of net sales. This recurring base insulates cash conversion from lab capital budget cycles and supported $539.81M in free cash flow in FY2025.678
Waters is experiencing strong demand for analytical testing of commercial GLP-1 therapeutics across both instrument platforms and consumables. Furthermore, biopharmaceutical supply chain reshoring across the U.S. and Europe represents a multi-year tailwind from 2027 to 2030, where Waters is positioned to capture lab expansions.5
Waters Corporation represents an exemplary wide-moat compounder with exceptional returns on capital and mission-critical biopharma integration, but its market valuation at $425.21 (as of 2026-10-02) incorporates overly demanding growth expectations. At a 23.13% premium to our fair value midpoint of $345.34 and an implied return of -18.78%, the stock offers an unfavorable risk-reward balance. We recommend reducing exposure and waiting for a more attractive valuation entry point.4
Waters Corporation is a global analytical laboratory instrument and software provider that designs, manufactures, sells, and services high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC), mass spectrometry (MS) systems, and thermal analysis instruments through its Waters and TA Instruments divisions. In FY2025, Waters instrument systems generated $1,101.83 million, TA instrument systems generated $243.82 million, and chemistry consumables added $631.46 million.
The company serves a broad customer base across pharmaceutical, life sciences, chemical materials, environmental, food, and academic sectors. Pharmaceutical customers represent the company's largest market, accounting for 59% of net sales in FY2025, 58% in 2024, and 57% in 2023. No single customer accounts for more than 2% of total annual sales, ensuring high customer diversification and negligible historical credit losses.
Geographically, revenue is well balanced across the Americas ($1,161.51 million or 36.7% of net sales in FY2025, with the United States generating $965.78 million), Europe ($963.38 million or 30.4%), and Asia-Pacific ($1,040.40 million or 32.9%, including $437.47 million in China).
Under a combined macroeconomic stress test reflecting simultaneous biopharma capital rationing and persistent Asian procurement friction, instrument placements decline sharply across the $1,977.10M product base. In this downside scenario, diluted EPS growth slows to 5.0% annually compared to consensus expectations of 13.47% for FY2027. Furthermore, FX headwinds absorbing $0.25 per share and distributor inventory adjustments compress operating margins below 23.0% (down from 25.36% in FY2025), reducing cash conversion and driving intrinsic equity value toward the downside boundary of $269.45.
Under the downside path, prolonged biopharmaceutical procurement delays constrain analytical instrument replacement, muting product sales growth. In addition, persistent hospital anti-corruption campaigns and DRG reforms in China delay tender releases, while peer discounting in routine QA/QC applications compresses operating margins below 23.0%. Foreign exchange translation drag of $0.25 per share further impedes cash conversion, constraining valuation toward the lower boundary.
Pharmaceutical customers generate 59.0% of net sales. If major pharma customers implement spending freezes on new analytical instruments ($1,977.10M product revenue) while peer Agilent aggressively discounts chromatography systems, Waters operating margin drops below 22.5% (down >300 bps from current 25.36%).378
Yatırım tezimizi zayıflatacak beş gelişme.
Operating margin falling below 22.50% would indicate aggressive competitive discounting from peers like Agilent or severe absorption losses from instrument volume declines, breaking structural profitability assumptions.
Güncel:25.36%
Şu durumda uyar< 22.50%
Waters Corporation's wide economic moat is anchored in the mission-critical nature of its analytical instruments within heavily regulated pharmaceutical and biotechnology environments. Approximately 59% of net sales are derived from pharmaceutical accounts, where liquid chromatography, mass spectrometry, and thermal analysis tools are deployed in commercial drug batch testing and release. Regulatory bodies like the FDA require drug developers to lock analytical methods into regulatory filings. Consequently, replacing a Waters instrument with a rival system introduces significant operational disruption, re-validation expense, and regulatory audit risk.
This structural lock-in is reinforced by an active installed base of 12,000 instruments ripe for replacement coupled with proprietary Empower software integration. Over 57% of consolidated revenues are recurring aftermarket revenue, comprising $631.46M in chemistry consumables and $1,188.19M in services in FY2025. These recurring revenue streams generate predictable, high-margin cash flows that insulate corporate returns during periods of customer capex deferrals.
While peer competitors such as Agilent operate at comparable operating margins (25.56% versus Waters 25.36% in FY2025), Waters achieves differentiated economic returns with an ROIC of 18.41% exceeding its computed WACC of 9.098%. Ongoing initiatives in reagent rental compliance across 700 accounts are increasing pricing realization from 90 bps toward 150 bps, sustaining the franchise's economic moat over our 15-year fade horizon.
Waters consistently generates returns on capital well above its cost of capital. The company achieved an ROIC of 18.41% compared to a computed WACC of 9.098% and a moderate cost of equity (Ke) of 9.6425%. This substantial economic profit spread of over 870 bps reflects structural pricing power and operating efficiency, supported by an operating income of $802.59M on $3,165.29M of revenue in FY2025.27
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
The highlighted cell is Fair value when every assumption sits at its base level ($345.34). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $1.1B after modeled reinvestment of $282.4M, with terminal value at 76.4% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
Under the modal base path, Waters delivers steady compound growth anchored by recurring chemistry consumables ($631.46M in FY2025) and service revenues ($1,188.19M). Top-line revenue expands from $6,466.84M in FY2026 to $7,136.40M in FY2027, while operating margins improve gradually toward long-term targets by FY2030 supported by 90 bps of pricing realization. Disciplined capital allocation and share buybacks offsetting SBC support diluted EPS progression from $14.58 in FY2026 to $16.54 in FY2027, yielding a synthesized fair value midpoint of $345.34.1578
A decisive beat driven by accelerating instrument replacements across the 12,000-unit installed base and pricing realization reaching 150 bps would warrant an upgrade to Hold as earnings power converges toward the upper fair value boundary ($440.18).
In-line financial performance confirms stable compounder execution but leaves the stock trading at a 23.1% premium to its fair value midpoint of $345.34, leaving the house rating unchanged.
An earnings miss driven by intensified biopharma capital freezes, prolonged China DRG headwinds, or elevated FX translation losses would confirm downside thesis risks, triggering multiple derating toward peer levels and necessitating a downgrade to Sell.
Waters exhibits high earnings quality supported by transparent GAAP reporting and superior cash conversion. FY2025 operating cash flow of $652.56M exceeded GAAP net income of $642.63M, yielding a cash conversion ratio of 101.5%. Stock-based compensation of $54.13M represents a modest 1.71% of revenue, well below the industry benchmark of 2.1%. Furthermore, the company has historically experienced minimal credit losses and negligible customer concentration.78
Pharma customers generate 59.0% of net sales; capital freezes directly constrain new instrument placements ($1,977.10M base).8
Waters demonstrates high-grade cash conversion. In FY2025, operating cash flow reached $652.56M, comfortably exceeding GAAP net income of $642.63M (conversion ratio of 101.5%). Capital expenditures were contained at $112.75M, resulting in free cash flow of $539.81M and an FCF margin of 17.05%. Working capital requirements remain modest, supporting strong owner earnings generation ($764.31M normalized owner earnings base) and consistent reinvestment in software and consumable manufacturing.67
Waters maintains strong structural return metrics, with an ROIC of 18.41% supported by disciplined operating margins (25.36% in FY2025) and an asset-light manufacturing profile. The trajectory remains stable as aftermarket service and consumable revenues sustain gross margins near 58-59%, offsetting cyclical fluctuations in new instrument placements.
At 18.41%, Waters ROIC generates an 871 bps spread above its computed WACC of 9.098% and an 817 bps spread above its moderate cost of equity of 9.6425%. This substantial excess return confirms genuine economic value creation through economic cycles.
| Gelir | $3.165.286.000 |
|---|---|
| Satışların maliyeti | $1.336.613.000 |
| Brüt kâr | $1.828.673.000 |
| Faaliyet giderleri | $1.026.085.000 |
| Faaliyet kârı | $802.588.000 |
| Faaliyet dışı kalemler ve vergiler | -$159.959.000 |
| Net kâr | $642.629.000 |
| Toplam varlıklar | $5.076.550.000 |
|---|---|
| Nakit | $587.831.000 |
| Dönen varlıklar | $2.147.645.000 |
| Toplam yükümlülükler | $2.515.308.000 |
| Kısa vadeli yükümlülükler | $1.239.499.000 |
| Özkaynaklar | $2.561.242.000 |
| Net kâr | $642.629.000 |
|---|---|
| Faaliyet nakit girişi | $902.993.000 |
| Amortisman ve itfa payları | $206.237.000 |
| Hisse bazlı ücretlendirme | $54.127.000 |
| Faaliyet nakit akışı | $652.555.000 |
| Faaliyet nakit çıkışı | $250.438.000 |
| Kullanılabilir nakit | $977.910.000 |
| Dönem başı nakit | $325.355.000 |
| Yatırım nakit çıkışı | $152.253.000 |
| Capex | $112.745.000 |
| Diğer yatırım faaliyetleri | $39.508.000 |
| Finansman nakit çıkışı | $237.205.000 |
| Hisse geri alımları | $14.667.000 |
| Net borç geri ödemesi | $220.000.000 |
| Diğer finansman faaliyetleri | $2.538.000 |
| Kur etkisi | $621.000 |
| Dönem sonu nakit | $587.831.000 |
| Yatırım nakit akışı | -$152.253.000 |
| Finansman nakit akışı | -$237.205.000 |
2026-10-03 tarihli analizde kullanılan belirli tarihe ait finansal veriler.
| Dönem | Gelir | EBITDA | Net kâr | Faaliyet nakit akışı | Serbest nakit akışı | Capex | Amortisman ve itfa payları | Hisse bazlı ücretlendirme | Hisse geri alımları | Ödenen temettüler | Net borç ihracı | Yatırım nakit akışı | Finansman nakit akışı | Dönem başı nakit | Dönem sonu nakit | Nakit ve yatırımlar | Toplam borç | Faaliyet marjı | ROIC | WACC | ROIC−WACC farkı |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $2,2 Mr | $741,5 Mn | $521,5 Mn | $642,9 Mn | $548 Mn | $95 Mn | $96,4 Mn | $41 Mn | $325,8 Mn | $0 | — | -$487,9 Mn | -$115,7 Mn | — | $505,6 Mn | $2,8 Mr | $1,8 Mr | %28,8 | — | %5,7 | — |
| 2017-12-31 | $2,3 Mr | $803,9 Mn | $20,3 Mn | $697,6 Mn | $607,2 Mn | $90,5 Mn | $106 Mn | $39,4 Mn | $332,5 Mn | $0 | — | -$535,8 Mn | -$63,9 Mn | $505,6 Mn | $642,3 Mn | $3,4 Mr | $2 Mr | %28,7 | — | %5,2 | — |
| 2018-12-31 | $2,4 Mr | $839,2 Mn | $593,8 Mn | $604,4 Mn | $476,9 Mn | $127,6 Mn | $108,4 Mn | $37,5 Mn | $1,3 Mr | — | — | $1,7 Mr | -$2,1 Mr | $642,3 Mn | $796,3 Mn | $1,7 Mr | $1,2 Mr | %30,6 | — | %6,0 | — |
| 2019-12-31 | $2,4 Mr | $832,2 Mn | $592,2 Mn | $643,1 Mn | $479,3 Mn | $163,8 Mn | $105,3 Mn | $38,6 Mn | $2,5 Mr | $53,7 Mn | — | $768,8 Mn | -$1,9 Mr | $796,3 Mn | $335,7 Mn | $337,1 Mn | $1,7 Mr | %29,4 | — | %5,7 | — |
| 2020-12-31 | $2,4 Mr | $785,3 Mn | $521,6 Mn | $790,5 Mn | $618,1 Mn | $172,4 Mn | $135,4 Mn | $36,9 Mn | $196,4 Mn | $66 Mn | — | -$264,1 Mn | -$440,5 Mn | $335,7 Mn | $436,7 Mn | $443,1 Mn | $1,4 Mr | %27,3 | — | %4,2 | — |
| 2021-12-31 | $2,8 Mr | $982,8 Mn | $692,8 Mn | $747,3 Mn | $579 Mn | $168,3 Mn | $131,7 Mn | $29,9 Mn | $648,9 Mn | $55,6 Mn | — | -$231,6 Mn | -$438,3 Mn | $436,7 Mn | $501,2 Mn | $569,3 Mn | $1,5 Mr | %29,5 | — | %4,9 | — |
| 2022-12-31 | $3 Mr | $1 Mr | $707,8 Mn | $611,7 Mn | $428,2 Mn | $183,5 Mn | $130,4 Mn | $42,6 Mn | $626,1 Mn | $42,8 Mn | $60 Mn | -$108 Mn | -$509,6 Mn | $501,2 Mn | $480,5 Mn | $481,4 Mn | $1,6 Mr | %29,4 | — | %7,3 | — |
| 2023-12-31 | $3 Mr | $817,7 Mn | $642,2 Mn | $602,8 Mn | $442,2 Mn | $160,6 Mn | $165,9 Mn | $36,9 Mn | $70,3 Mn | $1,6 Mr | $780 Mn | -$1,4 Mr | $755 Mn | $480,5 Mn | $395,1 Mn | $396 Mn | $2,4 Mr | %27,7 | — | %3,9 | — |
| 2024-12-31 | $3 Mr | $1 Mr | $637,8 Mn | $762,1 Mn | $619,6 Mn | $142,5 Mn | $191,8 Mn | $44,7 Mn | $13,5 Mn | — | -$730 Mn | -$143,1 Mn | -$696,7 Mn | $395,1 Mn | $325,4 Mn | $326,3 Mn | $1,6 Mr | %27,9 | — | %7,6 | — |
| 2025-12-31 | $3,2 Mr | $1 Mr | $642,6 Mn | $652,6 Mn | $539,8 Mn | $112,7 Mn | $206,2 Mn | $54,1 Mn | $14,7 Mn | — | -$220 Mn | -$152,3 Mn | -$237,2 Mn | $325,4 Mn | $587,8 Mn | $587,8 Mn | $1,4 Mr | %25,4 | — | %7,7 | — |
Waters Corporation (WAT) trades at 24.8x forward earnings against a peer median of 27.9x. Its EV/EBITDA of 32.2x compares with a peer median of 24.8x. The comparison uses 4 peers: Illumina Inc., IQVIA Holdings Inc., IDEXX Laboratories Inc. and Agilent Technologies Inc., as of 2026-10-03.
Industry capital intensity benchmarks show an industry capex-to-revenue ratio of 4.5% and a capex-to-depreciation ratio of 0.80x, confirming that broader life sciences instrument peers are restricting capital deployment below annual asset depreciation. Company-level capex of $112.75M against $206.24M in depreciation in FY2025 corroborates this disciplined reinvestment posture.
In an industry upcycle, biopharmaceutical R&D and manufacturing capital allocations expand briskly, prompting analytical labs to accelerate replacement cycles across the 12,000-unit installed base. High testing demand from emerging therapeutics such as GLP-1 peptides drives double-digit instrument shipment growth and enhances pull-through for premium consumables and service contracts.
In an industry downcycle, pharmaceutical sponsors implement capital expenditure freezes and lengthen analytical instrument replacement intervals beyond typical 7-10 year lifespans, dampening product sales ($1,977.10M base in FY2025). Concurrently, healthcare procurement reforms in key regions like China suppress public hospital tenders, while foreign exchange translation erodes reported operating profitability.
Waters is well positioned as a premium pure-play analytical technology provider. With 59% of revenue tied to pharmaceutical accounts and over 57% derived from high-margin recurring consumables and services ($1,819.64M combined), Waters exhibits superior earnings durability compared to peers during capital spending contractions. However, its premium valuation (24.75x forward P/E) leaves limited margin for error if lab capex recovery falters.48
Under the house Reduce rating, no fresh capital allocation is warranted as the share price of $425.21 (as of 2026-10-02) trades at a 23.13% premium to the synthesized fair value midpoint of $345.34. Investors holding existing positions should systematically trim or reallocate capital to higher-upside opportunities, maintaining underweight exposure until valuation multiples reflect an adequate margin of safety.4
Risk management focuses on mitigating capital loss from valuation multiple contraction and end-market procurement delays. Waters currently trades at 24.75x forward earnings, a substantial premium to peers such as IQVIA at 17.84x, leaving little tolerance for execution missteps. Given that 59% of sales depend on biopharmaceutical capital allocation, investors should monitor quarterly lab instrument placement trends, currency translation headwinds ($0.25 EPS drag in recent quarters), and China tender baselines. Portfolios should enforce disciplined stop-loss triggers and reallocate proceeds to assets offering positive implied returns.
Trading at $425.21 (as of 2026-10-02) or 24.75x forward P/E, the stock offers poor tactical risk-reward. A $0.25 FX drag on EPS and channel inventory unwinds create near-term volatility.45
The share price of $425.21 (as of 2026-10-02) reflects a 23.13% premium to our fair value midpoint of $345.34, with an implied return of -18.78%. Multi-stage cash flow modeling under a 9.10% WACC confirms valuation multiples are overextended.24
Waters possesses a wide economic moat rooted in high regulatory switching costs and 57.5% recurring revenue. Existing long-term investors may retain core positions for compounding but should avoid new capital commitments until valuation normalizes.8
Waters Corporation (WAT) is an elite life sciences instrumentation compounder, but its share price of $425.21 (as of 2026-10-02) stands at a 23.13% premium to our fair value estimate of $345.34, indicating an expected return of -18.78%.4
While Waters' wide economic moat remains intact—underpinned by 12,000 instruments ripe for replacement and 57.5% recurring revenue —trading at 24.75x forward earnings leaves the stock highly vulnerable to biopharma budget constraints, persistent China DRG headwinds, and foreign currency translation drag.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
China revenue of $437.47M represents 13.82% of sales, facing persistent headwinds from hospital anti-corruption campaigns and DRG reform. If Chinese lab spending remains suppressed and customers defer replacement across the 12,000 unit installed base, organic top-line revenue CAGR falls below 3.0% over 5 years.58
Waters currently trades at a forward P/E of 24.75x, while peer IQVIA trades at 17.84x. A 20% derating in the exit multiple from the modeled 22.0x down to 17.6x reflects multiple convergence toward lower-growth peers under sustained post-merger integration friction.34
A decline in biopharmaceutical revenue share below 50.0% would signal customer defection or structural share losses in QA/QC lot release testing, falsifying the core customer breadth thesis.
Güncel:59.0%
Şu durumda uyar< 50.0%
A sustained contraction exceeding 15% in China sales would indicate that DRG reforms and anti-corruption campaigns have evolved into structural market exclusion rather than transitory procurement timing.
Güncel:$437.47M base (13.8% of sales)
Şu durumda uyar< -15.0% YoY
A drop in combined chemistry consumables ($631.46M) and service ($1,188.19M) below 45% would indicate deteriorating consumable pull-through across active instruments, eroding cash flow predictability.
Güncel:57.5% of total net sales
Şu durumda uyar< 45.0%
Forward earnings multiple compressing below 17.60x would indicate valuation convergence toward lower-growth healthcare peers like IQVIA (17.84x), reflecting structural market multiple derating and prolonged growth deceleration.
Güncel:24.75x
Şu durumda uyar< 17.60x
| China Healthcare DRG Reform and Domestic Equipment Substitution | medium | 6 to 18 months | Management expects DRG reform headwinds to be fully absorbed in the baseline by Q4 2026, while launching the A7 platform to address ex-China competitive gaps.5 |
| Biotech Capital Spending Retrenchment and Replacement Deferrals | high | 12 to 18 months | Broad exposure across commercial biopharma manufacturing and GLP-1 testing, where no individual customer represents more than 2% of sales, mitigates single-market downturns.58 |
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and terminal value at WACC, then adjust for signed net debt per current share.
Discounted forecast-period cash flows ($89,63) plus discounted terminal value ($290) minus signed per current share ($8,37) equals the $371 lens value shown above. Negative net debt is , so subtracting it raises value.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Solve for the growth rate that makes the model value equal the report-date share price.
Under the upside trajectory, biopharmaceutical R&D and lab capital expenditure rebound sharply across North America and Europe, accelerating replacement across the 12,000-unit installed base. Expanding GLP-1 testing volumes and reagent rental compliance across 700 accounts lift pricing realization to 150 bps, while biopharma reshoring drives incremental lab placements through 2030. Operating margins expand toward 28-30%, supporting compound diluted EPS growth above consensus expectations toward the upper fair value boundary ($440.18).5
Pricing realization provides high-margin operating leverage, expanding from 90 bps toward the 150 bps corporate goal.5
A stronger USD eliminated 30 bps of operating margin and $0.25 of EPS, requiring ongoing cost actions to defend the 28.2% adjusted margin guide.5
| $7.71B |
| $8.21B |
| $8.62B |
| Revenue growth | 104.3% | 10.4% | 8.0% | 6.5% | 5.0% |
| Operating margin | 25.5% | 26.0% | 26.5% | 27.0% | 27.2% |
| Operating income | $1.65B | $1.86B | $2.04B | $2.22B | $2.34B |
| Tax rate | 14.4% | 14.4% | 14.4% | 14.4% | 14.4% |
| NOPAT | $1.41B | $1.59B | $1.75B | $1.90B | $2.01B |
| Reinvestment | $282.36M | $301.80M | $314.73M | $322.54M | $321.11M |
| Reinvestment rate (of NOPAT) | 20.0% | 19.0% | 18.0% | 17.0% | 16.0% |
| Free cash flow to firm | $1.13B | $1.29B | $1.43B | $1.57B | $1.69B |
| Terminal growth | 3.0% | 3.0% | 3.0% | 3.0% | 3.0% |
Capital allocation is disciplined and shareholder-focused. With total debt of $5,477.00M against a market cap of $41,749.61M (debt weight 11.6%), the balance sheet provides ample liquidity. Management prioritizes organic R&D investment, platform upgrades (such as the A7 and Empower platform), and selective technology tuck-ins, while utilizing free cash flow for share repurchases to offset annual stock-based compensation of $54.13M. Waters does not pay an ordinary cash dividend, channeling capital toward high-return internal initiatives and debt service.
In FY2025, chemistry consumables contributed $631.46M and service revenues generated $1,188.19M, together accounting for 57.5% of total sales ($3,165.29M).
Recurring aftermarket demand insulates operating profitability from capital expenditure cycles in biopharmaceutical laboratories and supports stable free cash flow conversion.
FY2025 operating income stood at $802.59M (25.36% margin), while Q2 2026 cost actions of $20M were offset by 30 bps of FX drag from a strong USD, which also absorbed $0.25 of EPS.
Underlying operating margin discipline remains intact, but foreign exchange volatility and channel inventory timing ($20M Q3 trade swing) create near-term quarterly earnings friction.
Management lifted pricing realization from 0.5% embedded guidance to 0.9% in Q2 2026 across 700 accounts, targeting 1.50% (150 bps) as systemic contract renegotiations progress.
Systemic pricing discipline provides margin expansion leverage toward our forecast target of 27.20% by FY2030, even amidst modest volume recovery.
| Marj |
|---|
| WAT | Waters Corporation | $41.7B | 24.8x | 9.0x | 32.2x | 1.9% | — |
| ILMN | Illumina Inc. | $41.2B | 44.7x | 9.2x | 36.9x | 32.3% | 21.1% |
| IQV | IQVIA Holdings Inc. | $42.5B | 17.8x | 2.5x | 18.6x | 22.8% | 13.0% |
| IDXX | IDEXX Laboratories Inc. | $40.9B | 31.0x | 9.0x | 25.7x | 74.2% | 35.0% |
| A | Agilent Technologies Inc. | $47.3B | 24.8x | 6.4x | 23.9x | 21.0% | 25.6% |
| Regulatory reforms such as China's hospital anti-corruption campaign and diagnosis-related group (DRG) hospital reimbursement reforms have delayed capital procurement decisions across Chinese analytical labs. |
| Provides an adequate margin of safety against potential macro headwinds and China DRG procurement delays. |
| $270.00 (Lower Valuation Bound / Downside Support) | Consider full position weighting for long-term compounder portfolios. |
| < 22.50% |
| Trigger immediate position divestment and model down terminal operating profitability to reflect structural pricing impairment. |
| China Net Sales Growth | < -15.0% YoY | Reduce international geographic revenue growth projections and lower five-year terminal cash flows.58 |
| Recurring Consumables and Service Share | < 45.0% of total revenue | Re-assess economic moat durability and revise terminal growth downward from 3.00% toward 2.00%.8 |
